Clinical Study of OR for Second-line Treatment of Refractory MZL

The goal of this clinical trial is to test the overall response rate of Orelabrutinib combined with rituximab (OR regimen) for second-line treatment of relapsed/refractory marginal zone lymphoma.

Trial Details

NCT ID
NCT06134284
Phase
PHASE4
Sponsor
Lixia Sheng
Status
RECRUITING
Cancer Type
Marginal Zone Lymphoma Lymphoma
Interventions
  • Orelabrutinib combined with rituximab
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142
  • Ningbo, Zhejiang, China|29.87819,121.54945
  • Ningbo, Zhejiang, China|29.87819,121.54945

Key Eligibility Criteria

  • Age: 18 years, 80, Sex gender no limitied;
  • histological confirmation of MZL, For splenic marginal zone lymphoma (SMZL) where histological specimens of the spleen were not available, Requirem…
  • at least one two-dimensional measurable lymph node lesion (CT scan or MR / display maximum diameter\> 1.5cm), Or at least one two-dimensional measu…
  • the investigator required systemic treatment for marginal zone lymphoma;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Marginal Zone Lymphoma Lymphoma Trials on Trialify →